<p>In a large international trial involving more than <strong>40,000</strong> adults aged 50 years and older, <span class="key-term" data-definition="Moderna — U.S. biotechnology firm that pioneered mRNA‑based COVID‑19 vaccines and is developing mRNA flu vaccines (GS3: Health/Science)">Moderna</span>'s seasonal influenza vaccine demonstrated superior efficacy compared with the standard‑dose vaccine from <span class="key-term" data-definition="GSK — GlaxoSmithKline, a multinational pharmaceutical company producing conventional flu vaccines (GS3: Health/Science)">GSK</span>. The study, published in the <em>New England Journal of Medicine</em>, reported a 26.6% higher effectiveness, surpassing the pre‑specified goal of non‑inferiority.</p>
<h3>Key Developments</h3>
<ul>
<li>The mRNA vaccine, designated <span class="key-term" data-definition="mRNA technology — Uses messenger RNA to instruct cells to produce viral proteins, enabling rapid vaccine design and production (GS3: Health/Science)">mRNA technology</span>, showed a modest increase in mild‑to‑moderate side‑effects such as injection‑site pain, fatigue, headache and muscle aches.</li>
<li>Severe adverse events were comparable between groups (2.2% with the mRNA shot vs 1.9% with the standard dose).</li>
<li>The U.S. <span class="key-term" data-definition="U.S. Food and Drug Administration — Federal agency that evaluates safety and efficacy of drugs and vaccines before market approval (GS3: Health, Governance)">FDA</span> rejected the initial application in February, citing the need for comparison with a <span class="key-term" data-definition="High‑dose flu vaccine — Influenza vaccine containing a higher antigen dose, recommended for adults ≥65 years due to better efficacy (GS3: Health)">high‑dose flu vaccine</span> for the ≥65 age group.</li>
<li>After discussions, the agency accepted an amended filing, with a commitment that Moderna will conduct an additional study in older adults post‑approval.</li>
<li>Regulatory reviews are also underway in the European Union, Canada and Australia.</li>
</ul>
<h3>Important Facts</h3>
<ul>
<li>Trial size: >40,000 participants, ages 50 +.</li>
<li>Efficacy gain: 26.6% over standard‑dose GSK vaccine.</li>
<li>Safety: Mostly mild‑to‑moderate reactions; severe events balanced across arms.</li>
<li>Decision deadline: <strong>August 5, 2026</strong> (FDA).</li>
<li>Potential first mRNA seasonal flu vaccine approved in the United States.</li>
<li>Anti‑vaccine activist <span class="key-term" data-definition="Robert F. Kennedy Jr. — Prominent anti‑vaccine activist who challenges mRNA technology, influencing public health discourse (GS4: Ethics/Polity)">Robert F. Kennedy Jr.</span> has called for heightened scrutiny of the technology.</li>
</ul>
<h3>UPSC Relevance</h3>
<p>The episode illustrates the intersection of science, public health policy, and regulatory governance—core themes for <strong>GS 3 (Health, Science & Technology)</strong> and <strong>GS 4 (Ethics, Governance)</strong>. Aspirants should note how novel vaccine platforms (mRNA) are evaluated against existing standards, the role of the <span class="key-term" data-definition="U.S. Food and Drug Administration — Federal agency that evaluates safety and efficacy of drugs and vaccines before market approval (GS3: Health, Governance)">FDA</span> in safeguarding public health, and how activist movements can shape policy debates.</p>
<h3>Way Forward</h3>
<p>If the FDA grants approval, the mRNA flu vaccine could set a precedent for faster, adaptable seasonal vaccines, prompting other manufacturers to invest in similar platforms. However, the requirement for an additional study in the ≥65 age group underscores the need for age‑specific efficacy data. Continuous monitoring of safety signals and transparent communication will be essential to counter misinformation propagated by anti‑vaccine figures.</p>
Loading page, please wait…